Theravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" Rating

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $14.50.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $10.63 on Friday. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.82. The stock has a market cap of $531.50 million, a PE ratio of -9.01 and a beta of -0.09. The firm's 50 day moving average price is $9.78 and its two-hundred day moving average price is $9.48.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The business had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. As a group, sell-side analysts predict that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the sale, the senior vice president now directly owns 336,918 shares in the company, valued at $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Newtyn Management LLC raised its holdings in shares of Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock worth $44,767,000 after acquiring an additional 258,337 shares during the period. Vanguard Group Inc. raised its holdings in shares of Theravance Biopharma by 3.5% during the first quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company's stock worth $18,579,000 after acquiring an additional 69,919 shares during the period. Park West Asset Management LLC raised its holdings in shares of Theravance Biopharma by 0.6% during the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock worth $16,112,000 after acquiring an additional 11,256 shares during the period. Geode Capital Management LLC raised its holdings in shares of Theravance Biopharma by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock worth $8,121,000 after acquiring an additional 4,823 shares during the period. Finally, D. E. Shaw & Co. Inc. increased its stake in Theravance Biopharma by 9.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock valued at $7,847,000 after buying an additional 69,178 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.